LIVIVO - Search results -

Search results

Result 1 - 10 of total 118

Search options

Article ; Online: Cancer survivors' experiences of a physical activity program in primary care: a qualitative study.

Huizinga, Famke / Kieboom, Eleonora A M / de Greef, Mathieu H G / Walenkamp, Annemiek M E / Berendsen, Annette J / Berger, Marjolein Y / Brandenbarg, Daan

Journal of cancer survivorship : research and practice

2024

Abstract: Purpose: This study aimed to gain insight into the experiences of, and reasons for, cancer survivors participating in a primary care PA program.: Methods: We interviewed 17 patients from 11 Dutch GP practices. Patients were selected by purposive ... ...

Abstract	Purpose: This study aimed to gain insight into the experiences of, and reasons for, cancer survivors participating in a primary care PA program. Methods: We interviewed 17 patients from 11 Dutch GP practices. Patients were selected by purposive sampling based on their general practice, gender, educational level, motivation for PA, and change in PA. Interviews were audio recorded, transcribed verbatim, and pseudonymized for inductive thematic analysis. Results: Three domains were identified with five themes: institutional domain: GP practice; program-specific domain: content sessions and PA, and activity tracker and goal setting; individual domain: experienced benefits, and personalized care needs. Participants valued the PA program because it was offered close to home, without additional costs, and by a trusted practice nurse familiar with the patients' medical background. Activity tracker use and goal setting motivated many participants but also led to demotivation and feelings of failure in others. Reported benefits included behavior change and favorable health outcomes. Many patients expressed the need to personalize psychological support and the program's timing. Conclusions: Access to a PA program in a primary care setting is valued for its accessibility and experienced health benefits, but also seems to meet an unmet need for support in picking up life during cancer recovery. Implications for cancer survivors: Primary care is important for continued care of cancer survivors. An accessible PA program in this setting may fulfil a need for not only lifestyle support but also continuing life after cancer treatment.
Language	English
Publishing date	2024-03-22
Publishing country	United States
Document type	Journal Article
ZDB-ID	2388888-X
ISSN	1932-2267 ; 1932-2259
ISSN (online)	1932-2267
ISSN	1932-2259
DOI	10.1007/s11764-024-01571-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Book ; Online: Chapter Modern Orthopaedic Implant Coatings - Their Pro's, Con's and Evaluation Methods

Welting, T.J. / H I M Walenkamp, Geert / Odekerken, Jim C. E. / Arts, Jacobus J. / Emans, Pieter J.

2013

Keywords	Environmental monitoring ; Technology, engineering, agriculture
Size	1 Online-Ressource
Publisher	InTechOpen
Document type	Book ; Online
Note	English ; Open Access
HBZ-ID	HT021047709
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: A homozygous mutation in the highly conserved Tyr60 of the mature IGF1 peptide broadens the spectrum of IGF1 deficiency.

Walenkamp, M J E / Wit, J M

European journal of endocrinology

2019 Volume 181, Issue 6, Page(s) C29–C33

MeSH term(s)	Growth Disorders/genetics ; Hearing Loss, Sensorineural/genetics ; Humans ; Insulin-Like Growth Factor I/deficiency ; Insulin-Like Growth Factor I/genetics ; Mutation/genetics ; Tyrosine/genetics
Chemical Substances	IGF1 protein, human ; Tyrosine (42HK56048U) ; Insulin-Like Growth Factor I (67763-96-6)
Language	English
Publishing date	2019-10-12
Publishing country	England
Document type	Journal Article
ZDB-ID	1183856-5
ISSN	1479-683X ; 0804-4643
ISSN (online)	1479-683X
ISSN	0804-4643
DOI	10.1530/EJE-19-0801
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.147: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Current Treatment Strategies and Future Directions for Extrapulmonary Neuroendocrine Carcinomas: A Review.

Stelwagen, Johannes / de Vries, Elisabeth G E / Walenkamp, Annemiek M E

JAMA oncology

2021 Volume 7, Issue 5, Page(s) 759–770

Abstract: Importance: Patients with extrapulmonary neuroendocrine carcinomas (EPNECs) receive essentially the same treatment as those with small cell lung cancer (SCLC) despite differences in origin, clinical course, and survival. This SCLC-based approach is ... ...

Abstract	Importance: Patients with extrapulmonary neuroendocrine carcinomas (EPNECs) receive essentially the same treatment as those with small cell lung cancer (SCLC) despite differences in origin, clinical course, and survival. This SCLC-based approach is attributable to the rarity of EPNECs, which impedes the use of randomized clinical trials. However, neuroendocrine carcinomas are becoming more common because of the increasing use of systemic cancer therapy for adenocarcinomas. This treatment can transdifferentiate certain adenocarcinomas into neuroendocrine carcinomas. In addition, the treatment landscape for SCLC is slowly changing, potentially impacting the treatment paradigms for EPNECs. Observations: New information on tumorigenesis of EPNECs from different origins, either as a primary malignant tumor or after neuroendocrine differentiation from adenocarcinomas, demonstrates their biological similarity. Activated molecular pathways that appear to underlie the development of EPNECs are potentially targetable, and some of these targets, such as poly(adenosine diphosphate-ribose) polymerase, Wee1, and Aurora A kinase, are currently under investigation. Immune checkpoint inhibitors (ICIs) already constituted a new treatment modality for patients with SCLC and produced some promising results in patients with EPNECs. Conclusions and relevance: Although only moderately effective, the introduction of ICIs signifies the first new option in systemic treatment of SCLC in decades. To prove the value of ICIs and other new drugs for patients with EPNECs, these patients should be included in clinical trials independent of the primary tumor site. Furthermore, to optimize clinical decision-making for patients with EPNECs, experts from the neuroendocrine tumor board should collaborate with members from tumor site-specific boards, which will require patient referral to a center with EPNEC expertise.
MeSH term(s)	Carcinoma, Neuroendocrine/drug therapy ; Humans ; Immunotherapy/methods ; Lung Neoplasms/drug therapy ; Neuroendocrine Tumors/drug therapy ; Small Cell Lung Carcinoma/drug therapy ; Small Cell Lung Carcinoma/pathology
Language	English
Publishing date	2021-03-22
Publishing country	United States
Document type	Journal Article ; Review
ISSN	2374-2445
ISSN (online)	2374-2445
DOI	10.1001/jamaoncol.2020.8072
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: The immune tumour microenvironment of neuroendocrine tumours and its implications for immune checkpoint inhibitors.

Takkenkamp, Tim J / Jalving, Mathilde / Hoogwater, Frederik J H / Walenkamp, Annemiek M E

Endocrine-related cancer

2020 Volume 27, Issue 9, Page(s) R329–R343

Abstract: Immunotherapy in the form of immune checkpoint inhibitors (ICIs) has transformed the treatment landscape in numerous types of advanced cancer. However, the majority of patients do not benefit from this treatment modality. Although data are scarce, in ... ...

Abstract	Immunotherapy in the form of immune checkpoint inhibitors (ICIs) has transformed the treatment landscape in numerous types of advanced cancer. However, the majority of patients do not benefit from this treatment modality. Although data are scarce, in general, patients with low-grade neuroendocrine tumours (NETs) do not benefit from treatment with ICIs in contrast to patients with neuroendocrine carcinoma, in which a small subgroup of patients may benefit. Low- and intermediate-grade NETs predominantly lack factors associated with response to ICIs treatment, like immune cell infiltration, and have an immunosuppressive tumour metabolism and microenvironment. In addition, because of its potential influence on the response to ICIs, major interest has been shown in the tryptophan-degrading enzymes indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO). These enzymes work along the kynurenine pathway that deplete tryptophan in the tumour microenvironment. IDO and TDO are especially of interest in NETs since some tumours produce serotonin but the majority do not, which potentially deplete the precursor tryptophan. In this review, we summarize the current knowledge on the immune tumour microenvironment of neuroendocrine tumours and implications for treatment with immune checkpoint inhibitors. We also discuss (targetable) factors in the NET tumour microenvironment that potentially modulate the anti-cancer immune response.
MeSH term(s)	Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Neuroendocrine Tumors/drug therapy ; Tumor Microenvironment
Chemical Substances	Immune Checkpoint Inhibitors
Language	English
Publishing date	2020-06-24
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	1218450-0
ISSN	1479-6821 ; 1351-0088
ISSN (online)	1479-6821
ISSN	1351-0088
DOI	10.1530/ERC-20-0113
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4192: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Implementation and evaluation of a physical activity counselling programme in primary care among cancer survivors: SoDA study protocol.

Huizinga, Famke / Westerink, Nico-Derk Lodewijk / Berendsen, Annette J / Walenkamp, Annemiek M E / de Greef, Mathieu H G / de Bock, Geertruida H / Berger, Marjolein Y / Brandenbarg, Daan

BMJ open

2022 Volume 12, Issue 3, Page(s) e060098

Abstract: Introduction: Physical activity (PA) favourably affects various health outcomes in cancer survivors, but little is known about how to implement a PA programme in primary care. We therefore aim to implement and evaluate such a programme for cancer ... ...

Abstract	Introduction: Physical activity (PA) favourably affects various health outcomes in cancer survivors, but little is known about how to implement a PA programme in primary care. We therefore aim to implement and evaluate such a programme for cancer survivors in general practice. Methods and analyses: The Stimulation of Daily Activity study is an implementation study with a single-arm longitudinal design in 15 Dutch general practices. Patients aged ≥18 years who finished cancer treatment more than 6 months ago will be eligible for inclusion. The intervention will comprise six coaching sessions with the practice nurse in 9 months, seeking to increase PA in daily activities and using an activity tracker for goal setting and feedback. The Ethics and dissemination: The Medical Research Ethics Committee of the University Medical Centre Groningen, the Netherlands, concluded that this study was not subject to the Dutch Medical Research Involving Human Subjects Act (registration number: 201900586). The study results will be made available to patients and general practitioners via (inter)national publications and conferences, newsletters, public summaries and via (social) media.
MeSH term(s)	Adolescent ; Adult ; Cancer Survivors ; Counseling ; Exercise ; General Practice ; Humans ; Neoplasms/therapy ; Primary Health Care
Language	English
Publishing date	2022-03-02
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2599832-8
ISSN	2044-6055 ; 2044-6055
ISSN (online)	2044-6055
ISSN	2044-6055
DOI	10.1136/bmjopen-2021-060098
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: At the Bedside: Profiling and treating patients with CXCR4-expressing cancers.

Martin, Miguel / Mayer, Ingrid A / Walenkamp, Annemiek M E / Lapa, Constantin / Andreeff, Michael / Bobirca, Alexandra

Journal of leukocyte biology

2020 Volume 109, Issue 5, Page(s) 953–967

Abstract: ... To date, Sanofi Genzyme's plerixafor is the only marketed CXCR4 inhibitor (i.e ... Functions of CXCR4 in Cancer. J. Leukoc. Biol. xx: xx-xx; 2020. ...

Abstract	The chemokine receptor, C-X-C chemokine receptor type 4 (CXCR4) and its ligand, C-X-C motif chemokine 12, are key mediators of hematopoietic cell trafficking. Their roles in the proliferation and metastasis of tumor cells, induction of angiogenesis, and invasive tumor growth have been recognized for over 2 decades. CXCR4 is a promising target for imaging and therapy of both hematologic and solid tumors. To date, Sanofi Genzyme's plerixafor is the only marketed CXCR4 inhibitor (i.e., Food and Drug Administration-approved in 2008 for stem cell mobilization). However, several new CXCR4 inhibitors are now being investigated as potential therapies for a variety of fluid and solid tumors. These small molecules, peptides, and Abs include balixafortide (POL6326, Polyphor), mavorixafor (X4P-001, X4 Pharmaceuticals), motixafortide (BL-8040, BioLineRx), LY2510924 (Eli Lilly), and ulocuplumab (Bristol-Myers Squibb). Early clinical evidence has been encouraging, for example, with motixafortide and balixafortide, and the CXCR4 inhibitors appear to be generally safe and well tolerated. Molecular imaging is increasingly being used for effective patient selection before, or early during CXCR4 inhibitor treatment. The use of radiolabeled theranostics that combine diagnostics and therapeutics is an additional intriguing approach. The current status and future directions for radioimaging and treating patients with CXCR4-expressing hematologic and solid malignancies are reviewed. See related review - At the Bench: Pre-Clinical Evidence for Multiple Functions of CXCR4 in Cancer. J. Leukoc. Biol. xx: xx-xx; 2020.
MeSH term(s)	Antineoplastic Agents/therapeutic use ; Clinical Trials as Topic ; Humans ; Neoplasms/drug therapy ; Peptides/therapeutic use ; Receptors, CXCR4/antagonists & inhibitors ; Receptors, CXCR4/metabolism
Chemical Substances	Antineoplastic Agents ; CXCR4 protein, human ; Peptides ; Receptors, CXCR4
Language	English
Publishing date	2020-10-22
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	605722-6
ISSN	1938-3673 ; 0741-5400
ISSN (online)	1938-3673
ISSN	0741-5400
DOI	10.1002/JLB.5BT1219-714R
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 603: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: The effects of molar activity on [

Stormezand, Gilles N / Schreuder, Romano S B H / Brouwers, Adrienne H / Slart, Riemer H J A / Elsinga, Philip H / Walenkamp, Annemiek M E / Dierckx, R A J O / Glaudemans, Andor W J M / Luurtsema, Gert

EJNMMI research

2021 Volume 11, Issue 1, Page(s) 88

Abstract: Background: 6-[: Aims: This study aimed to investigate whether the difference in molar activity affects the [: Methods: We retrospectively analyzed 49 patients with pathologically confirmed NETs and stable disease who underwent PET scanning using ... ...

Abstract	Background: 6-[ Aims: This study aimed to investigate whether the difference in molar activity affects the [ Methods: We retrospectively analyzed 49 patients with pathologically confirmed NETs and stable disease who underwent PET scanning using both [ Results: Comparable or slightly higher uptake was demonstrated in various physiological uptake sites in subjects scanned with [ Conclusion: [18F]FDOPA-H provides a higher activity yield, offering the possibility to scan more patients with one single production. Minor differences were observed in SUV's, with slight increases in uptake of [
Language	English
Publishing date	2021-09-08
Publishing country	Germany
Document type	Journal Article
ZDB-ID	2619892-7
ISSN	2191-219X
ISSN	2191-219X
DOI	10.1186/s13550-021-00829-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Molecular IGF-1 and IGF-1 receptor defects: from genetics to clinical management.

Walenkamp, M J E / Losekoot, M / Wit, J M

Endocrine development

2013 Volume 24, Page(s) 128–137

Abstract: Molecular defects of the insulin-like growth factor 1 gene (IGF1) are rare in the human. Only three homozygous and two families with heterozygous mutations of the IGF1 gene have been described, resulting in a variable degree of intrauterine and postnatal ...

Abstract	Molecular defects of the insulin-like growth factor 1 gene (IGF1) are rare in the human. Only three homozygous and two families with heterozygous mutations of the IGF1 gene have been described, resulting in a variable degree of intrauterine and postnatal growth retardation, microcephaly, developmental delay and deafness. Detailed genetic analysis and functional experiments have shown that IGF-1 plays a key role in pre- and postnatal growth and development in human. Eleven patients with heterozygous and 2 patients with compound heterozygous mutations in the type 1 IGF1 receptor gene (IGF1R) have been reported. Intrauterine and postnatal growth retardation, microcephaly and IGF-1 levels above the mean of age references are consistent findings in these patients, although IGF-1 levels can be low initially because of feeding problems. The first reported patients showed the most severe phenotype, but with the identification of additional patients the phenotype appears to be more variable. The functional effect of the defects has been studied by in vitro experiments. From these studies, receptor haploinsufficiency, decreased IGF1R biosynthesis, interference with ligand binding and transmembrane signaling, and disruption of the intrinsic tyrosine kinase activity have been suggested as possible mechanisms with a variable pathogenetic spectrum. Data on GH treatment in these children are limited, showing a poor to modest growth response.
MeSH term(s)	Animals ; Birth Weight/genetics ; Female ; Fetal Growth Retardation/genetics ; Growth Disorders/diagnosis ; Growth Disorders/genetics ; Growth Disorders/therapy ; Humans ; Infant, Newborn ; Insulin-Like Growth Factor I/genetics ; Models, Biological ; Mutation/physiology ; Pregnancy ; Receptor, IGF Type 1/genetics
Chemical Substances	Insulin-Like Growth Factor I (67763-96-6) ; Receptor, IGF Type 1 (EC 2.7.10.1)
Language	English
Publishing date	2013
Publishing country	Switzerland
Document type	Journal Article ; Review
ISSN	1662-2979 ; 1421-7082
ISSN (online)	1662-2979
ISSN	1421-7082
DOI	10.1159/000342841
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Intrauterine Twin Discordancy and Partial Postnatal Catch-up Growth in a Girl with a Pathogenic

Ocaranza, Paula / Losekoot, Monique / Walenkamp, Marie J. E. / De Bruin, Christiaan / Wit, Jan M. / Mericq, Veronica

Journal of clinical research in pediatric endocrinology

2019 Volume 11, Issue 3, Page(s) 293–300

Abstract: Objective: Insulin like growth factors-1 (IGF-1) is essential for normal : Methods: A girl born with a low weight and length [-2.3 and -2.4 standard deviation (SD) score (SDS), respectively] but borderline low head circumference (-1.6 SD) presented ... ...

Abstract	Objective: Insulin like growth factors-1 (IGF-1) is essential for normal Methods: A girl born with a low weight and length [-2.3 and -2.4 standard deviation (SD) score (SDS), respectively] but borderline low head circumference (-1.6 SD) presented with a height of -1.7 SDS, in contrast to a normal height twin brother (0.0 SDS). IGF-1 resistance was suspected because of elevated serum IGF-1 levels. Results: Sequencing revealed the presence of a previously described pathogenic heterozygous mutation (p.Glu1050Lys) in the SGA girl which was not present in the parents nor in the AGA twin brother. Conclusion: The pathogenic
MeSH term(s)	Body Height ; Failure to Thrive/blood ; Failure to Thrive/genetics ; Failure to Thrive/pathology ; Female ; Fetal Growth Retardation/blood ; Fetal Growth Retardation/genetics ; Fetal Growth Retardation/pathology ; Gestational Age ; Humans ; Infant, Newborn ; Infant, Small for Gestational Age/blood ; Infant, Small for Gestational Age/growth & development ; Insulin-Like Growth Factor I/analysis ; Male ; Mutation ; Prognosis ; Receptor, IGF Type 1/genetics ; Twins, Dizygotic
Chemical Substances	IGF1R protein, human ; Insulin-Like Growth Factor I (67763-96-6) ; Receptor, IGF Type 1 (EC 2.7.10.1)
Language	English
Publishing date	2019-03-12
Publishing country	Turkey
Document type	Case Reports ; Journal Article
ZDB-ID	2641608-6
ISSN	1308-5735 ; 1308-5727
ISSN (online)	1308-5735
ISSN	1308-5727
DOI	10.4274/jcrpe.galenos.2019.2018.0236
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6942: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito